BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Johnson & Johnson readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Johnson & Johnson's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05757869-11184@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:Milvexian: Phase 3 readout est. (NCT05757869)
DESCRIPTION:Milvexian\, phase 3.\nStudy: A Study of Milvexian Versus Apixab
 an in Participants With Atrial Fibrillation\nEstimated primary completion:
  8 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mil
 vexian#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05757869
URL:https://assetmemo.bio/drug/milvexian#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544616-685@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:ACI-35.030: Phase 2 readout est. (NCT06544616)
DESCRIPTION:ACI-35.030\, phase 2\, Alzheimer's Disease.\nStudy: A Study of 
 JNJ-64042056 in Participants With Preclinical Alzheimer's Disease\nEstimat
 ed primary completion: 22 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/aci-35-030#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06544616
URL:https://assetmemo.bio/drug/aci-35-030#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04658862-2285@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cetrelimab: Phase 3 readout est. (NCT04658862)
DESCRIPTION:Cetrelimab\, phase 3\, Bladder Cancer.\nStudy: A Study of TAR-2
 00 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in P
 articipants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cetrelimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04658862
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559306-802@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Seltorexant: Phase 3 readout est. (NCT06559306)
DESCRIPTION:Seltorexant\, phase 3\, Major Depressive Disorder.\nStudy: Phas
 e 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Pa
 rticipants With Major Depressive Disorder and Insomnia Symptoms\nEstimated
  primary completion: 30 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/seltorexant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06559306
URL:https://assetmemo.bio/drug/seltorexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05908734-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05908734)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Combination Therapy With Amivantamab and Cetrelimab in Participa
 nts With Metastatic Non-small Cell Lung Cancer\nEstimated primary completi
 on: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05908734
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179876-515@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Opsumit (Macitentan): Phase 3 readout est. (NCT05179876)
DESCRIPTION:Opsumit (Macitentan)\, phase 3.\nStudy: A Study Providing Treat
 ment Access in Participants With Pulmonary Hypertension Completing a Paren
 t Study and Having no Other Option\nEstimated primary completion: 31 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/macitentan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05179
 876
URL:https://assetmemo.bio/drug/macitentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260163-5@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06260163)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Study of Guselkumab in Pediatric Participants With Moderately to Severely 
 Active Ulcerative Colitis\nEstimated primary completion: 10 February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06260163
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807424-19@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT06807424)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) 
 in Biologic-experienced and Biologic-naive Participants With Active Psoria
 tic Arthritis\nEstimated primary completion: 10 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/icotrokinra#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06807424
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-2289@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of JN
 J-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed A
 gainst B-cell Maturation Antigen (BCMA) in Participants With Multiple Myel
 oma\nEstimated primary completion: 26 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480383-708@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06480383)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generaliz
 ed Anxiety Disorder\nEstimated primary completion: 16 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06480383
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347095-5@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05347095)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Participants With Fistulizing\, Perianal Crohn's Disea
 se\nEstimated primary completion: 25 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05347095
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850689-872@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT05850689)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: Study of Lumateperone as Adjunctive Therapy in the Treatment of Pat
 ients With Major Depressive Disorder\nEstimated primary completion: 5 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0585
 0689
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379595-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05379595)
DESCRIPTION:Amivantamab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy 
 in Participants With Advanced or Metastatic Colorectal Cancer\nEstimated p
 rimary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05379595
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488314-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05488314)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Capmatinib Combination Therapy in Unresectable M
 etastatic Non-small Cell Lung Cancer\nEstimated primary completion: 28 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0548
 8314
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-2019@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06120140)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Enha
 nced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth
  Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated
  First-line With Amivantamab Plus Lazertinib\nEstimated primary completion
 : 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lazert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06120140
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408935-5@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06408935)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: Trans
 mural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Diseas
 e Patients\nEstimated primary completion: 8 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06408935
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266441-3310@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Ramantamig: Phase 2 readout est. (NCT07266441)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: A Study of JNJ
 -79635322 in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 14 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07266441
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06690398-872@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06690398)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder in Pediatric Patients\nEstimated primary completion: 21 June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06690
 398
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706674-872@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06706674)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder (ASD) in Pediatric Patients\nEstimated primary completion: 2
 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumatepe
 rone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06706674
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04634552-3135@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Talquetamab: Phase 2 readout est. (NCT04634552)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ta
 lquetamab in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04634552
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-2289@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Talquetamab in Combination With Daratumumab or in Combination With Da
 ratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalido
 mide and Dexamethasone in Participants With Multiple Myeloma That Returns 
 After Treatment or is Resistant to Treatment\nEstimated primary completion
 : 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/darat
 umumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05455320
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2019@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Lazertinib: Phase 2 readout est. (NCT05498428)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Participants With Advanced or Metastatic Solid Tumor
 s Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell
  Lung Cancer\nEstimated primary completion: 17 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550895-3135@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06550895)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ci
 ltacabtagene Autoleucel and Talquetamab for the Treatment of Participants 
 With High-Risk Multiple Myeloma\nEstimated primary completion: 26 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06550895
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092269-6@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Stelara (ustekinumab): Phase 3 readout est. (NCT05092269)
DESCRIPTION:Stelara (ustekinumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-term Extension Study of Ustekinumab in Pediatric Participants\nEstim
 ated primary completion: 29 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05092269
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701903-708@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06701903)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized
  Anxiety Disorder\nEstimated primary completion: 14 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06701903
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923073-5@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20271027
DTEND;VALUE=DATE:20271028
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05923073)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Pediatric Participants With Moderately to Severely Act
 ive Crohn's Disease\nEstimated primary completion: 27 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05923073
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-11218@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Pasritamig: Phase 3 readout est. (NCT07225946)
DESCRIPTION:Pasritamig\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Docetaxel in 
 Participants With Metastatic Castration-Resistant Prostate Cancer\nEstimat
 ed primary completion: 19 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05963074-2041@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05963074)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A S
 tudy to Customize Ibrutinib Treatment Regimens for Participants With Previ
 ously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completion
 : 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05963074
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750094-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06750094)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Partici
 pants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previou
 sly Received Chemotherapy\nEstimated primary completion: 15 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06750094
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651567-708@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06651567)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease Agitation.\nStu
 dy: A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment
  of Agitation Associated With Alzheimer's Dementia\nEstimated primary comp
 letion: 28 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/deulumateperone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06651567
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196748-19@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280114
DTEND;VALUE=DATE:20280115
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT07196748)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With
  Moderately to Severely Active Ulcerative Colitis\nEstimated primary compl
 etion: 14 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/icotrokinra#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07196748
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906717-11219@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:JNJ-101556143: Phase 3 readout est. (NCT07906717)
DESCRIPTION:JNJ-101556143\, phase 3\, Prostate Cancer.\nStudy: A Study of J
 NJ-101556143 With Best Supportive Care in Participants With Metastatic Pro
 state Cancer\nEstimated primary completion: 14 February 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/jnj-101556143#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07906717
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2019@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Lazertinib: Phase 2 readout est. (NCT07586202)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in P
 articipants With Resectable EGFR-Mutated NSCLC\nEstimated primary completi
 on: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/laz
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07586202
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05316155-2255@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Erdafitinib (Balversa): Phase 1/2 readout est. (NCT05316155)
DESCRIPTION:Erdafitinib (Balversa)\, phase 1/2.\nStudy: Study of Erdafitini
 b Intravesical Delivery System for Localized Bladder Cancer\nEstimated pri
 mary completion: 30 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/erdafitinib-balversa#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05316155
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919965-11225@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:TAR-210: Phase 3 readout est. (NCT06919965)
DESCRIPTION:TAR-210\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy:
  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in
  Participants With High Risk Non-Muscle-Invasive Bladder Cancer\nEstimated
  primary completion: 6 April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tar-210#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06919965
URL:https://assetmemo.bio/drug/tar-210#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149857-3161@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT07149857)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel\nEst
 imated primary completion: 12 April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07149857
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07577843-22@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:JNJ-78934804: Phase 3 readout est. (NCT07577843)
DESCRIPTION:JNJ-78934804\, phase 3\, Crohn's Disease.\nStudy: A Study of JN
 J-78934804 in Participants With Moderately to Severely Active Crohn's Dise
 ase\nEstimated primary completion: 12 June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/jnj-78934804#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07577843
URL:https://assetmemo.bio/drug/jnj-78934804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319820-11225@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280628
DTEND;VALUE=DATE:20280629
SUMMARY:TAR-210: Phase 3 readout est. (NCT06319820)
DESCRIPTION:TAR-210\, phase 3.\nStudy: A Study to Evaluate TAR-210 Versus S
 ingle Agent Intravesical Cancer Treatment in Participants With Bladder Can
 cer\nEstimated primary completion: 28 June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tar-210#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06319820
URL:https://assetmemo.bio/drug/tar-210#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892173-2634@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:NBTXR3: Phase 3 readout est. (NCT04892173)
DESCRIPTION:NBTXR3\, phase 3.\nStudy: JNJ-90301900 (NBTXR3) Activated by Ra
 diotherapy With or Without Cetuximab in LA-HNSCC\nEstimated primary comple
 tion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 btxr3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04892173
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07577856-22@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:JNJ-78934804: Phase 3 readout est. (NCT07577856)
DESCRIPTION:JNJ-78934804\, phase 3\, Ulcerative Colitis.\nStudy: A Study of
  JNJ-78934804 in Participants With Moderately to Severely Active Ulcerativ
 e Colitis\nEstimated primary completion: 11 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/jnj-78934804#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07577856
URL:https://assetmemo.bio/drug/jnj-78934804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06800313-11219@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:JNJ-101556143: Phase 1/2 readout est. (NCT06800313)
DESCRIPTION:JNJ-101556143\, phase 1/2\, Prostate Cancer.\nStudy: Study of H
 LD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer\nEstim
 ated primary completion: 17 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/jnj-101556143#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06800313
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164443-11218@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280818
DTEND;VALUE=DATE:20280819
SUMMARY:Pasritamig: Phase 3 readout est. (NCT07164443)
DESCRIPTION:Pasritamig\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of Pasritamig With or Without JNJ-87189401 Versus
  Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mC
 RPC)\nEstimated primary completion: 18 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07164443
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573176-802@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280824
DTEND;VALUE=DATE:20280825
SUMMARY:Seltorexant: Phase 3 readout est. (NCT07573176)
DESCRIPTION:Seltorexant\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Seltorexant as Monotherapy in Adults and Elderly Participants With 
 Major Depressive Disorder\nEstimated primary completion: 24 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/seltorexant#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07573176
URL:https://assetmemo.bio/drug/seltorexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196722-19@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Icotyde (icotrokinra): Phase 2/3 readout est. (NCT07196722)
DESCRIPTION:Icotyde (icotrokinra)\, phase 2/3\, Crohn's Disease.\nStudy: A 
 Study of Icotrokinra in Participants With Moderately to Severely Active Cr
 ohn's Disease\nEstimated primary completion: 19 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/icotrokinra#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196722
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540833-708@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06540833)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease.\nStudy: A Stud
 y to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psycho
 sis Associated With Alzheimer's Disease\nEstimated primary completion: 30 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/deulu
 mateperone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06540833
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499232-5@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT07499232)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab Versus Risankizumab in Participants With Moderately to Se
 verely Active Crohn's Disease\nEstimated primary completion: 15 November 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07499232
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227025-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT07227025)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Olomorasib Combination Therapy in Participants W
 ith Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 3
 0 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiv
 antamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07227025
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258511-3310@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20281212
DTEND;VALUE=DATE:20281213
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07258511)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study Compar
 ing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecif
 ic Antibody in Participants With Relapsed or Refractory Multiple Myeloma\n
 Estimated primary completion: 12 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07258511
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662786-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06662786)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIR
 I as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-typ
 e Unresectable or Metastatic Left-sided Colorectal Cancer\nEstimated prima
 ry completion: 15 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06662786
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716098-800@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Spravato (Esketamine): Phase 3 readout est. (NCT07716098)
DESCRIPTION:Spravato (Esketamine)\, phase 3\, Major Depressive Disorder.\nS
 tudy: A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Part
 icipants With Treatment-resistant Depression\nEstimated primary completion
 : 27 December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 sketamine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07716098
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04811560-3019@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:bleximenib: Phase 1/2 readout est. (NCT04811560)
DESCRIPTION:bleximenib\, phase 1/2.\nStudy: A Phase 1/2 Study of Bleximenib
  in Participants With Acute Leukemia (cAMeLot-1)\nEstimated primary comple
 tion: 29 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bleximenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04811560
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667908-2634@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:NBTXR3: Phase 2 readout est. (NCT06667908)
DESCRIPTION:NBTXR3\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidati
 on Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nbtxr3#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06667908
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-2289@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\nEstimated primary completion: 31 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3161@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Ciltacabtagene autoleucel: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study of Bortezomib\, Lenalidomide and Dexamethasone (VRd) Followed by 
 Cilta-cel\, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by L
 enalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diag
 nosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEs
 timated primary completion: 14 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518186-3310@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07518186)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study Compar
 ing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refracto
 ry Multiple Myeloma\nEstimated primary completion: 29 April 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ramantamig#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07518186
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832292-11219@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290517
DTEND;VALUE=DATE:20290518
SUMMARY:JNJ-101556143: Phase 2 readout est. (NCT07832292)
DESCRIPTION:JNJ-101556143\, phase 2\, Prostate Cancer.\nStudy: A Study of J
 NJ-101556143 in Participants With Metastatic Prostate Cancer\nEstimated pr
 imary completion: 17 May 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/jnj-101556143#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07832292
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2019@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06667076)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Combination With Lazertinib\, or Amivantamab in Comb
 ination With Platinum-Based Chemotherapy\, for Common Epidermal Growth Fac
 tor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276399-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:Amivantamab: Phase 3 readout est. (NCT07276399)
DESCRIPTION:Amivantamab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Study of Amivantamab in Addition to Standard of Care Agents (SOC
 ) Compared With SOC Alone in Participants With Recurrent/Metastatic Head a
 nd Neck Cancer\nEstimated primary completion: 18 June 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07276399
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06852222-3019@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:bleximenib: Phase 3 readout est. (NCT06852222)
DESCRIPTION:bleximenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Bleximenib\, Venetoclax and Azacitidine For Treatment of Participants W
 ith Newly Diagnosed Acute Myeloid Leukemia (AML)\nEstimated primary comple
 tion: 22 June 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 leximenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06852222
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746687-1400@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290911
DTEND;VALUE=DATE:20290912
SUMMARY:JNJ-95597528: Phase 2 readout est. (NCT07746687)
DESCRIPTION:JNJ-95597528\, phase 2.\nStudy: A Study of JNJ-95597528 in Part
 icipants With Inadequately Controlled Moderate to Severe Asthma\nEstimated
  primary completion: 11 September 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/jnj-95597528#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07746687
URL:https://assetmemo.bio/drug/jnj-95597528#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714202-2285@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290918
DTEND;VALUE=DATE:20290919
SUMMARY:Cetrelimab: Phase 3 readout est. (NCT05714202)
DESCRIPTION:Cetrelimab\, phase 3\, Bladder Cancer.\nStudy: A Study of TAR-2
 00 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bac
 illus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non
 -muscle Invasive Bladder Cancer (HR-NMIBC)\nEstimated primary completion: 
 18 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 trelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05714202
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747389-872@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT07747389)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: A Study of Lumateperone Versus Placebo in Participants With Major D
 epressive Disorder\nEstimated primary completion: 20 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07747389
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807865-708@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20300218
DTEND;VALUE=DATE:20300219
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07807865)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as 
 an Additional Treatment in Participants With Generalized Anxiety Disorder 
 (GAD)\nEstimated primary completion: 18 February 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/deulumateperone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07807865
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500884-3310@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Ramantamig: Phase 2 readout est. (NCT06500884)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: A Study to Eva
 luate Preventive Treatments for GPRC5D-related Oral Events\nEstimated prim
 ary completion: 30 May 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ramantamig#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06500884
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-2289@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Di
 fferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumum
 ab and Teclistamab in Combination With Daratumumab Following Induction Wit
 h Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participant
 s With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary c
 ompletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665450-2289@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07665450)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Ra
 mantamig Plus Daratumumab Versus Daratumumab\, Bortezomib\, Lenalidomide\,
  and Dexamethasone (DVRd) or Daratumumab\, Lenalidomide\, and Dexamethason
 e (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Pla
 nned\nEstimated primary completion: 4 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07665450
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856420-708@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20300920
DTEND;VALUE=DATE:20300921
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07856420)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Partic
 ipants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Resp
 onse to GAD Treatment\nEstimated primary completion: 20 September 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07856420
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227454-800@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20310409
DTEND;VALUE=DATE:20310410
SUMMARY:Spravato (Esketamine): Phase 3 readout est. (NCT07227454)
DESCRIPTION:Spravato (Esketamine)\, phase 3\, Major Depressive Disorder.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of Esketamine for Reduct
 ion of Symptoms of Major Depressive Disorder\nEstimated primary completion
 : 9 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/esket
 amine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07227454
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-2289@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Ta
 lquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Par
 ticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05552222
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372964-872@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06372964)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Bipolar Depression.\nStudy: 
 Multicenter Study of Lumateperone for the Treatment of Bipolar Depression 
 in Pediatric Patients\nEstimated primary completion: 31 October 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06372964
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663332-5@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20311212
DTEND;VALUE=DATE:20311213
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06663332)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants\nE
 stimated primary completion: 12 December 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06663332
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229210-872@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20320428
DTEND;VALUE=DATE:20320429
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06229210)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Schizophrenia.\nStudy: Safet
 y and Tolerability Trial of Lumateperone in Pediatric Patients With Schizo
 phrenia\, Bipolar Disorder or Autism Spectrum Disorder\nEstimated primary 
 completion: 28 April 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lumateperone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06229210
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385080-2020@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20321227
DTEND;VALUE=DATE:20321228
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT06385080)
DESCRIPTION:Amivantamab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Amivantamab Alone or in Addition to Other Treatment A
 gents in Participants With Head and Neck Cancer\nEstimated primary complet
 ion: 27 December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06385080
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903272-2289@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20370111
DTEND;VALUE=DATE:20370112
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07903272)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Trial Compa
 ring Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab\, Bortez
 omib\, Lenalidomide\, and Dexamethasone in Participants With Newly Diagnos
 ed Multiple Myeloma Who Are Transplant Eligible\nEstimated primary complet
 ion: 11 January 2037. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07903272
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
